{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:00:13Z","timestamp":1793289613035,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jtho.2023.04.021","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T21:11:51Z","timestamp":1683148311000},"page":"1055-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tudor-Eliade","family":"Ciuleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Mahave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Alexandru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Pluzanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes Bernabe","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Linardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Martinez-Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Axelrod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Borghaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Bushong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi G.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik J.","family":"Grootendorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie R.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2023.04.021_bib1","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.3747\/co.20.1481","article-title":"Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases","volume":"20","author":"Ali","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jamaoncol.2016.3834","article-title":"Estimating survival in patients with lung cancer and brain metastases: an update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)","volume":"3","author":"Sperduto","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib3","doi-asserted-by":"crossref","first-page":"S795","DOI":"10.1016\/S1556-0864(21)02022-0","article-title":"Abstract 180P: incidence of brain metastases (BM) in newly diagnosed stage IV NSCLC during COVID-19","volume":"16","author":"Cui","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib4","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1016\/j.cllc.2018.01.007","article-title":"Non-small-cell lung cancer with brain metastasis at presentation","volume":"19","author":"Waqar","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.lungcan.2015.11.011","article-title":"Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: analysis from the European FRAME study","volume":"90","author":"Moro-Sibilot","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11095-018-2455-9","article-title":"Barriers to effective drug treatment for brain metastases: a multifactorial problem in the delivery of precision medicine","volume":"35","author":"Kim","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.jtho.2023.04.021_bib7","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.021_bib8","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib9","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib11","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1\u2013positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001. 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2023.04.021_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jtho.2022.10.014","article-title":"First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations","volume":"18","author":"Paz-Ares","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021,\u00a0\u2212189, and\u00a0\u2212407","volume":"16","author":"Powell","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.04.021_bib14","article-title":"Abstract CT221: nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: results from CheckMate 227","volume":"80","author":"Borghaei","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2023.04.021_bib15","doi-asserted-by":"crossref","first-page":"S862","DOI":"10.1016\/j.jtho.2021.08.061","article-title":"Abstract OA09.01: first-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: results from CheckMate 9LA","volume":"16","author":"Carbone","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"suppl 16","key":"10.1016\/j.jtho.2023.04.021_bib16","doi-asserted-by":"crossref","first-page":"9010","DOI":"10.1200\/JCO.2022.40.16_suppl.9010","article-title":"Updated analysis from the ATEZO-BRAIN trial: atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non\u2013small cell lung cancer with untreated brain metastases","volume":"40","author":"Nadal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib17","doi-asserted-by":"crossref","first-page":"S1430","DOI":"10.1016\/j.annonc.2021.10.141","article-title":"Abstract 122MO: nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): intracranial and systemic outcomes from CheckMate 227 Part 1","volume":"32","author":"Reck","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib19","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.021_bib20","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2023.04.021_bib25","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Non-Small Cell Lung Cancer V.1.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 20, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.jtho.2023.04.021_bib26","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtho.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 Part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib30","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1343774","article-title":"Alternative metrics for assessing clinical benefit with immunotherapy in oncology","volume":"8","author":"Chan","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2023.04.021_bib32","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jtho.2016.07.017","article-title":"Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-PD-1\/PD-L1 antibodies","volume":"11","author":"Shukuya","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib33","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib34","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a020412","article-title":"The blood-brain barrier","volume":"7","author":"Daneman","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jtho.2023.04.021_bib35","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jpba.2018.10.025","article-title":"Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid","volume":"164","author":"Pluim","year":"2019","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.jtho.2023.04.021_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s12885-019-5741-y","article-title":"Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review","volume":"19","author":"van Bussel","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib38","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1158\/1078-0432.CCR-20-0798","article-title":"PD-1\/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice","volume":"26","author":"Eguren-Santamaria","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2023.04.021_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2023.04.021_bib40","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in\u00a0vivo","volume":"194","author":"Das","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jtho.2023.04.021_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jtho.2023.04.021_bib42","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Central Nervous System Cancers V.2.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed January 20, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.jtho.2023.04.021_bib43","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/JTO.0b013e3181c59a3a","article-title":"Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer","volume":"5","author":"Edelman","year":"2010","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2023.04.021_bib45","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/annonc\/mdr003","article-title":"Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07\u201301)","volume":"22","author":"Barlesi","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423005257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086423005257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T20:57:15Z","timestamp":1719953835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086423005257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1556086423005257"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2023.04.021","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2023.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}